Stock Analysts

J&J’s Erleada Meets Both Primary Endpoints in Late-Stage Study

Johnson & Johnson’s JNJ subsidiary announced the unblinding of a phase III study evaluating its newly launched prostate cancer drug, Erleada (apalutamide) plus androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). Erleada is presently marketed in the United States for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. It was approved in EU for the same indication in January 2019. […]